Published in Psychopharmacology (Berl) on January 09, 2009
Dopamine, behavioral economics, and effort. Front Behav Neurosci (2009) 1.91
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav (2012) 1.33
Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PLoS One (2012) 1.11
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation. Mol Psychiatry (2013) 1.08
Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy. Neuropharmacology (2011) 1.02
Xanthines as adenosine receptor antagonists. Handb Exp Pharmacol (2011) 0.96
Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia. Neurosci Biobehav Rev (2013) 0.95
Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behav Brain Res (2009) 0.95
Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience (2010) 0.91
Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology (Berl) (2013) 0.87
Dopamine/adenosine interactions involved in effort-related aspects of food motivation. Appetite (2009) 0.86
Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms. Int J Neuropsychopharmacol (2014) 0.84
Dopamine, effort, and decision making: theoretical comment on Bardgett et al. (2009). Behav Neurosci (2009) 0.84
Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. Psychopharmacology (Berl) (2011) 0.83
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci (2013) 0.82
Effect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum rat. Psychopharmacology (Berl) (2010) 0.79
The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology (Berl) (2014) 0.78
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One (2014) 0.78
Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists. Psychopharmacology (Berl) (2015) 0.78
Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. Psychopharmacology (Berl) (2016) 0.78
Neural substrates underlying effort, time, and risk-based decision making in motivated behavior. Neurobiol Learn Mem (2016) 0.78
Wheel running alters patterns of uncontrollable stress-induced cfos mRNA expression in rat dorsal striatum direct and indirect pathways: A possible role for plasticity in adenosine receptors. Behav Brain Res (2014) 0.77
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation. Psychopharmacology (Berl) (2015) 0.77
Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior. Neuropsychopharmacology (2015) 0.76
Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat. Psychopharmacology (Berl) (2015) 0.75
Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions. Psychopharmacology (Berl) (2017) 0.75
Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) (2007) 4.73
Corticostriatal-hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav (2005) 3.47
Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res (2002) 3.40
Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol (2005) 2.57
Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology (Berl) (2007) 2.33
Weighing up the benefits of work: behavioral and neural analyses of effort-related decision making. Neural Netw (2006) 2.33
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
Functional specialization within medial frontal cortex of the anterior cingulate for evaluating effort-related decisions. J Neurosci (2003) 2.20
Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine. Psychopharmacology (Berl) (2006) 2.03
Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res (1992) 1.96
Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res (1994) 1.96
Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem (2002) 1.88
Amygdala-prefrontal cortical circuitry regulates effort-based decision making. Cereb Cortex (2006) 1.83
A role for mesencephalic dopamine in activation: commentary on Berridge (2006). Psychopharmacology (Berl) (2006) 1.78
Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol (1999) 1.76
Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem (1991) 1.69
Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev (1997) 1.69
Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology (Berl) (1991) 1.65
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort. Psychopharmacology (Berl) (2004) 1.58
Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci (2008) 1.52
Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology (Berl) (2006) 1.52
D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption. Pharmacol Biochem Behav (2001) 1.50
Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology (2003) 1.48
The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol (2004) 1.38
Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride, and fenfluramine on a concurrent choice task. Psychopharmacology (Berl) (2002) 1.34
Nucleus accumbens dopamine depletions alter relative response allocation in a T-maze cost/benefit task. Behav Brain Res (1996) 1.30
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun (2008) 1.30
Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord (2004) 1.27
Nucleus accumbens dopamine and work requirements on interval schedules. Behav Brain Res (2002) 1.26
Ratio and time requirements on operant schedules: effort-related effects of nucleus accumbens dopamine depletions. Eur J Neurosci (2005) 1.22
Involvement of catecholamine neurotransmission in the rat anterior cingulate in effort-related decision making. Behav Neurosci (2005) 1.21
The role of accumbens dopamine in lever pressing and response allocation: effects of 6-OHDA injected into core and dorsomedial shell. Pharmacol Biochem Behav (1998) 1.19
Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) (1997) 1.19
Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. J Neurosci (2008) 1.17
Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci (2008) 1.12
Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology (Berl) (2007) 1.11
Role of muscles accumbens dopamine D1 and D2 receptors in instrumental and Pavlovian paradigms of conditioned reward. Psychopharmacology (Berl) (2000) 1.10
Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat. Pharmacol Biochem Behav (1993) 1.10
Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology (Berl) (2006) 1.07
Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats. Psychopharmacology (Berl) (2008) 1.06
Forebrain circuitry involved in effort-related choice: Injections of the GABAA agonist muscimol into ventral pallidum alter response allocation in food-seeking behavior. Neuroscience (2008) 1.05
Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem (2004) 1.03
Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl) (2005) 1.03
Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative and stimulant drugs. Psychopharmacology (Berl) (1994) 1.03
Motor depressant effects mediated by dopamine D2 and adenosine A2A receptors in the nucleus accumbens and the caudate-putamen. Eur J Pharmacol (1997) 1.02
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci (2005) 1.02
The antinociceptive effect of 2-chloro-2'-C-methyl-N6-cyclopentyladenosine (2'-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat. Pain (2007) 1.01
The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res (2004) 0.99
Modulation of short-term social memory in rats by adenosine A1 and A(2A) receptors. Neurosci Lett (2004) 0.98
Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci (2001) 0.96
The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology (Berl) (2008) 0.95
Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. J Pharmacol Exp Ther (1998) 0.95
Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord (2001) 0.95
Rats assess costs and benefits according to an internal standard. Behav Brain Res (2006) 0.94
Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav Brain Res (2006) 0.94
Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci (2008) 0.92
Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.92
Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behav Brain Res (2004) 0.88
Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.88
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci (2001) 0.88
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse (2001) 0.88
Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat Disord (2008) 0.87
Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A(2A) receptors. Eur J Pharmacol (1999) 0.86
The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology (Berl) (2005) 0.86
Mood disorders. Neuroimaging Clin N Am (2007) 0.85
Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology (1999) 0.85
Effects of haloperidol and d-amphetamine on perceived quantity of food and tones. Psychopharmacology (Berl) (1987) 0.83
Participation of adenosine system in the ketamine-induced motor activity in mice. Pharmacol Rep (2005) 0.78
Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology (2006) 0.78
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Neurobiology of exercise. Obesity (Silver Spring) (2006) 3.39
Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med (2012) 2.46
CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation (2007) 2.09
Dopamine, behavioral economics, and effort. Front Behav Neurosci (2009) 1.91
Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J (2007) 1.84
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal (2013) 1.71
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
P2 receptors activated by uracil nucleotides--an update. Curr Med Chem (2006) 1.62
Adenosine receptor antagonists including caffeine alter fetal brain development in mice. Sci Transl Med (2013) 1.46
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem (2002) 1.44
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology (2003) 1.41
Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs (2003) 1.39
The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav (2012) 1.33
Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem (2004) 1.27
Nucleus accumbens dopamine and work requirements on interval schedules. Behav Brain Res (2002) 1.26
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Ratio and time requirements on operant schedules: effort-related effects of nucleus accumbens dopamine depletions. Eur J Neurosci (2005) 1.22
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology (2008) 1.20
Accumbens dopamine and the regulation of effort in food-seeking behavior: modulation of work output by different ratio or force requirements. Behav Brain Res (2004) 1.17
Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. J Neurosci (2008) 1.17
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem (2006) 1.17
Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. Nat Protoc (2010) 1.16
Rapid and efficient microwave-assisted copper(0)-catalyzed ullmann coupling reaction: general access to anilinoanthraquinone derivatives. Org Lett (2007) 1.15
Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol (2009) 1.15
Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem (2004) 1.15
Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PLoS One (2012) 1.11
Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol (2005) 1.10
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
Comparison between multiple behavioral effects of peripheral ethanol administration in rats: sedation, ataxia, and bradykinesia. Life Sci (2006) 1.07
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem (2009) 1.07
Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology (Berl) (2006) 1.07
Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J Nat Prod (2002) 1.06
Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats. Psychopharmacology (Berl) (2008) 1.06
Piecing together the puzzle of acetaldehyde as a neuroactive agent. Neurosci Biobehav Rev (2011) 1.05
Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther (2003) 1.05
Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol Biochem Behav (2005) 1.04
Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem (2004) 1.03
Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl) (2005) 1.03
A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signal (2005) 1.01
Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav (2006) 1.01
Imidazo[2,1-b]thiazepines: synthesis, structure and evaluation of benzodiazepine receptor binding. Eur J Med Chem (2004) 0.98
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem (2009) 0.98
Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharmacol Exp Ther (2009) 0.97
Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett (2002) 0.97
The role of acetaldehyde in the central effects of ethanol. Alcohol Clin Exp Res (2005) 0.95
Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia. Neurosci Biobehav Rev (2013) 0.95
Functions of mesolimbic dopamine: changing concepts and shifting paradigms. Psychopharmacology (Berl) (2006) 0.95
The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology (Berl) (2008) 0.95
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem (2002) 0.95
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem (2009) 0.95
Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behav Brain Res (2009) 0.95
Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem (2006) 0.95
Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. Biochem Pharmacol (2003) 0.95
Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav Brain Res (2006) 0.94
Nucleus accumbens neurotransmission and effort-related choice behavior in food motivation: effects of drugs acting on dopamine, adenosine, and muscarinic acetylcholine receptors. Neurosci Biobehav Rev (2013) 0.93
A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl) (2005) 0.93
Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem (2004) 0.93
Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg Med Chem Lett (2005) 0.92
Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addict Biol (2010) 0.92
Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum. Exp Neurol (2011) 0.92
N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. J Med Chem (2012) 0.92
Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase. J Med Chem (2009) 0.91
Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J Neurosci (2013) 0.91
Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse (2003) 0.91
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem (2010) 0.91
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem (2006) 0.91
GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J (2010) 0.91
P2Y₂ and Gq/G₁₁ control blood pressure by mediating endothelial mechanotransduction. J Clin Invest (2015) 0.91
Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 0.90
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett (2007) 0.90
Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling. Anal Bioanal Chem (2005) 0.89
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J Med Chem (2002) 0.89
The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors. Biochem Pharmacol (2013) 0.89
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J Med Chem (2009) 0.88
Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol (2007) 0.88
2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res (2002) 0.88
Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem (2010) 0.88
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem (2013) 0.88
Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor. J Comput Aided Mol Des (2009) 0.88
Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. J Clin Invest (2014) 0.87
Extracellular NAD(+) induces a rise in [Ca(2+)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors. Cell Calcium (2009) 0.87
Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology (Berl) (2013) 0.87
Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure (2012) 0.87